Mireille Mousseau - Concepedia

Author

Mireille Mousseau

Centre Hospitalier Universitaire de Grenoble

Also Known As

Delphine Loirat, Mireille Mousseau, Mousseau Mireille, Mousseau, Mireille

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire de Grenoble Centre Léon Bérard Université Grenoble Alpes Inserm Hôpital Albert Michallon

About

Mireille Mousseau is an author at Centre Hospitalier Universitaire de Grenoble specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	1.4K
2	Cell Biology	2	2	172
3	Health Sciences	1	1	578
4	Biochemistry	1	1	135
5	Cellular Physiology	1	1	135

Mireille Mousseau

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma Sylvie Négrier, Bernard Escudier, Christine Lasset, New England Journal of Medicine	1998	965
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study Xavier Pivot, Joseph Gligorov, Volkmar Müller, Annals of Oncology Breast OncologyOncologyConventional Intravenous InfusionBreast CancerSubcutaneous Trastuzumab	2014	169
Rotenone Inhibits the Mitochondrial Permeability Transition-induced Cell Death in U937 and KB Cells Christiane Chauvin, Frédéric De Oliveira, Xavier Ronot, Journal of Biological Chemistry MitophagyCell DeathRedox BiologyCellular PhysiologyPtp Regulation	2001	135
New advances in DPYD genotype and risk of severe toxicity under capecitabine Marie-Christine Étienne-Grimaldi, Jean-Christophe Boyer, Christophe Béroud, PLoS ONE	2017	102
Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin Michel Faber, Charles Coudray, H. Hida, Biological Trace Element Research Trace Element StatusMedicinePharmacologyPathologyAnti-cancer Agent	1995	95
5-Hydroxymethyluracil excretion, plasma tbars and plasma antioxidant vitamins in adriamycin-treated patients Henri Faure, Charles Coudray, Mireille Mousseau, Free Radical Biology and Medicine Plasma TbarsMedicine5-Hydroxymethyluracil ExcretionPharmacologyPlasma Antioxidant Vitamins	1996	68
Randomized Multicenter Phase II Study Comparing a Combination of Fluorouracil and Folinic Acid and Alternating Irinotecan and Oxaliplatin With Oxaliplatin and Irinotecan in Fluorouracil-Pretreated Metastatic Colorectal Cancer Patients Y. Bécouarn, Érick Gamelin, Bruno Coudert, Journal of Clinical Oncology	2001	61
Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure Antonin Schmitt, Laurence Gladieff, Céline M. Laffont, Journal of Clinical Oncology	2010	55
The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein Christine Rebischung, R Barnoud, Laëtitia Stefani, Gastric Cancer Tumor BiologyC-erbb-2 ProteinMedicinePathologyImmune Checkpoint Inhibitor	2005	52

Page 1